nodes	percent_of_prediction	percent_of_DWPC	metapath
Bepridil—Sudden death—Teniposide—lymphatic system cancer	0.0423	0.0423	CcSEcCtD
Bepridil—Sinus bradycardia—Mitoxantrone—lymphatic system cancer	0.0231	0.0231	CcSEcCtD
Bepridil—Sudden death—Mitoxantrone—lymphatic system cancer	0.0221	0.0221	CcSEcCtD
Bepridil—Depression—Mechlorethamine—lymphatic system cancer	0.0164	0.0164	CcSEcCtD
Bepridil—Liver function test abnormal—Teniposide—lymphatic system cancer	0.0145	0.0145	CcSEcCtD
Bepridil—Cardiac failure—Fludarabine—lymphatic system cancer	0.0142	0.0142	CcSEcCtD
Bepridil—Tinnitus—Mechlorethamine—lymphatic system cancer	0.0138	0.0138	CcSEcCtD
Bepridil—Liver function test abnormal—Fludarabine—lymphatic system cancer	0.0128	0.0128	CcSEcCtD
Bepridil—Loss of libido—Methotrexate—lymphatic system cancer	0.0122	0.0122	CcSEcCtD
Bepridil—Angina pectoris—Fludarabine—lymphatic system cancer	0.0116	0.0116	CcSEcCtD
Bepridil—Sweating—Teniposide—lymphatic system cancer	0.0116	0.0116	CcSEcCtD
Bepridil—Vertigo—Mechlorethamine—lymphatic system cancer	0.0115	0.0115	CcSEcCtD
Bepridil—Sudden death—Methotrexate—lymphatic system cancer	0.011	0.011	CcSEcCtD
Bepridil—Arthritis—Bleomycin—lymphatic system cancer	0.0104	0.0104	CcSEcCtD
Bepridil—Anorexia—Mechlorethamine—lymphatic system cancer	0.00999	0.00999	CcSEcCtD
Bepridil—Arrhythmia—Teniposide—lymphatic system cancer	0.00972	0.00972	CcSEcCtD
Bepridil—Pharyngitis—Fludarabine—lymphatic system cancer	0.00949	0.00949	CcSEcCtD
Bepridil—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.00911	0.00911	CcSEcCtD
Bepridil—Arrhythmia—Fludarabine—lymphatic system cancer	0.00854	0.00854	CcSEcCtD
Bepridil—Cardiac failure—Mitoxantrone—lymphatic system cancer	0.00843	0.00843	CcSEcCtD
Bepridil—Hypertension—Teniposide—lymphatic system cancer	0.00818	0.00818	CcSEcCtD
Bepridil—Liver function test abnormal—Carmustine—lymphatic system cancer	0.00817	0.00817	CcSEcCtD
Bepridil—Oedema—Teniposide—lymphatic system cancer	0.00773	0.00773	CcSEcCtD
Bepridil—Hyperhidrosis—Teniposide—lymphatic system cancer	0.00747	0.00747	CcSEcCtD
Bepridil—Anorexia—Teniposide—lymphatic system cancer	0.00737	0.00737	CcSEcCtD
Bepridil—Cough—Fludarabine—lymphatic system cancer	0.00726	0.00726	CcSEcCtD
Bepridil—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00717	0.00717	CcSEcCtD
Bepridil—Myalgia—Fludarabine—lymphatic system cancer	0.00709	0.00709	CcSEcCtD
Bepridil—Dyspnoea—Teniposide—lymphatic system cancer	0.00689	0.00689	CcSEcCtD
Bepridil—Depression—Carmustine—lymphatic system cancer	0.0068	0.0068	CcSEcCtD
Bepridil—Oedema—Fludarabine—lymphatic system cancer	0.00679	0.00679	CcSEcCtD
Bepridil—Erectile dysfunction—Vincristine—lymphatic system cancer	0.00672	0.00672	CcSEcCtD
Bepridil—Decreased appetite—Teniposide—lymphatic system cancer	0.00672	0.00672	CcSEcCtD
Bepridil—Rash—Mechlorethamine—lymphatic system cancer	0.00661	0.00661	CcSEcCtD
Bepridil—Dermatitis—Mechlorethamine—lymphatic system cancer	0.0066	0.0066	CcSEcCtD
Bepridil—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00657	0.00657	CcSEcCtD
Bepridil—Erectile dysfunction—Mitoxantrone—lymphatic system cancer	0.00655	0.00655	CcSEcCtD
Bepridil—Depression—Vincristine—lymphatic system cancer	0.00649	0.00649	CcSEcCtD
Bepridil—Anorexia—Fludarabine—lymphatic system cancer	0.00647	0.00647	CcSEcCtD
Bepridil—Drowsiness—Mitoxantrone—lymphatic system cancer	0.00634	0.00634	CcSEcCtD
Bepridil—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00632	0.00632	CcSEcCtD
Bepridil—Sweating—Vincristine—lymphatic system cancer	0.00624	0.00624	CcSEcCtD
Bepridil—Nausea—Mechlorethamine—lymphatic system cancer	0.00623	0.00623	CcSEcCtD
Bepridil—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00619	0.00619	CcSEcCtD
Bepridil—Abdominal pain—Teniposide—lymphatic system cancer	0.00611	0.00611	CcSEcCtD
Bepridil—Body temperature increased—Teniposide—lymphatic system cancer	0.00611	0.00611	CcSEcCtD
Bepridil—Paraesthesia—Fludarabine—lymphatic system cancer	0.0061	0.0061	CcSEcCtD
Bepridil—Sweating—Mitoxantrone—lymphatic system cancer	0.00607	0.00607	CcSEcCtD
Bepridil—Dyspnoea—Fludarabine—lymphatic system cancer	0.00606	0.00606	CcSEcCtD
Bepridil—Dyspepsia—Fludarabine—lymphatic system cancer	0.00598	0.00598	CcSEcCtD
Bepridil—Decreased appetite—Fludarabine—lymphatic system cancer	0.0059	0.0059	CcSEcCtD
Bepridil—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00586	0.00586	CcSEcCtD
Bepridil—Constipation—Fludarabine—lymphatic system cancer	0.00581	0.00581	CcSEcCtD
Bepridil—Pain—Fludarabine—lymphatic system cancer	0.00581	0.00581	CcSEcCtD
Bepridil—Bradycardia—Mitoxantrone—lymphatic system cancer	0.00579	0.00579	CcSEcCtD
Bepridil—Rhinitis—Mitoxantrone—lymphatic system cancer	0.0057	0.0057	CcSEcCtD
Bepridil—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.00565	0.00565	CcSEcCtD
Bepridil—Asthenia—Teniposide—lymphatic system cancer	0.00554	0.00554	CcSEcCtD
Bepridil—Arrhythmia—Carmustine—lymphatic system cancer	0.00547	0.00547	CcSEcCtD
Bepridil—Cardiac disorder—Vincristine—lymphatic system cancer	0.00542	0.00542	CcSEcCtD
Bepridil—Body temperature increased—Fludarabine—lymphatic system cancer	0.00537	0.00537	CcSEcCtD
Bepridil—Cough—Bleomycin—lymphatic system cancer	0.00532	0.00532	CcSEcCtD
Bepridil—Diarrhoea—Teniposide—lymphatic system cancer	0.00529	0.00529	CcSEcCtD
Bepridil—Myalgia—Bleomycin—lymphatic system cancer	0.00519	0.00519	CcSEcCtD
Bepridil—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.00508	0.00508	CcSEcCtD
Bepridil—Vision blurred—Carmustine—lymphatic system cancer	0.00502	0.00502	CcSEcCtD
Bepridil—Tremor—Carmustine—lymphatic system cancer	0.00499	0.00499	CcSEcCtD
Bepridil—Oedema—Bleomycin—lymphatic system cancer	0.00498	0.00498	CcSEcCtD
Bepridil—Asthenia—Fludarabine—lymphatic system cancer	0.00487	0.00487	CcSEcCtD
Bepridil—Rash—Teniposide—lymphatic system cancer	0.00487	0.00487	CcSEcCtD
Bepridil—Dermatitis—Teniposide—lymphatic system cancer	0.00487	0.00487	CcSEcCtD
Bepridil—Headache—Teniposide—lymphatic system cancer	0.00484	0.00484	CcSEcCtD
Bepridil—Anorexia—Bleomycin—lymphatic system cancer	0.00475	0.00475	CcSEcCtD
Bepridil—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00467	0.00467	CcSEcCtD
Bepridil—Diarrhoea—Fludarabine—lymphatic system cancer	0.00465	0.00465	CcSEcCtD
Bepridil—Hypertension—Carmustine—lymphatic system cancer	0.0046	0.0046	CcSEcCtD
Bepridil—Nausea—Teniposide—lymphatic system cancer	0.00459	0.00459	CcSEcCtD
Bepridil—Vertigo—Vincristine—lymphatic system cancer	0.00457	0.00457	CcSEcCtD
Bepridil—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00454	0.00454	CcSEcCtD
Bepridil—Myalgia—Carmustine—lymphatic system cancer	0.00453	0.00453	CcSEcCtD
Bepridil—Anxiety—Carmustine—lymphatic system cancer	0.00452	0.00452	CcSEcCtD
Bepridil—Paraesthesia—Bleomycin—lymphatic system cancer	0.00447	0.00447	CcSEcCtD
Bepridil—Dyspnoea—Bleomycin—lymphatic system cancer	0.00444	0.00444	CcSEcCtD
Bepridil—Hypertension—Vincristine—lymphatic system cancer	0.00439	0.00439	CcSEcCtD
Bepridil—Oedema—Carmustine—lymphatic system cancer	0.00435	0.00435	CcSEcCtD
Bepridil—Decreased appetite—Bleomycin—lymphatic system cancer	0.00433	0.00433	CcSEcCtD
Bepridil—Myalgia—Vincristine—lymphatic system cancer	0.00433	0.00433	CcSEcCtD
Bepridil—Cough—Mitoxantrone—lymphatic system cancer	0.00432	0.00432	CcSEcCtD
Bepridil—Rash—Fludarabine—lymphatic system cancer	0.00428	0.00428	CcSEcCtD
Bepridil—Dermatitis—Fludarabine—lymphatic system cancer	0.00428	0.00428	CcSEcCtD
Bepridil—Hypertension—Mitoxantrone—lymphatic system cancer	0.00428	0.00428	CcSEcCtD
Bepridil—Pain—Bleomycin—lymphatic system cancer	0.00426	0.00426	CcSEcCtD
Bepridil—Headache—Fludarabine—lymphatic system cancer	0.00425	0.00425	CcSEcCtD
Bepridil—Myalgia—Mitoxantrone—lymphatic system cancer	0.00422	0.00422	CcSEcCtD
Bepridil—Anxiety—Mitoxantrone—lymphatic system cancer	0.0042	0.0042	CcSEcCtD
Bepridil—Oedema—Vincristine—lymphatic system cancer	0.00415	0.00415	CcSEcCtD
Bepridil—Anorexia—Carmustine—lymphatic system cancer	0.00414	0.00414	CcSEcCtD
Bepridil—Oedema—Mitoxantrone—lymphatic system cancer	0.00404	0.00404	CcSEcCtD
Bepridil—Nausea—Fludarabine—lymphatic system cancer	0.00403	0.00403	CcSEcCtD
Bepridil—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00401	0.00401	CcSEcCtD
Bepridil—Shock—Mitoxantrone—lymphatic system cancer	0.00398	0.00398	CcSEcCtD
Bepridil—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00396	0.00396	CcSEcCtD
Bepridil—Anorexia—Vincristine—lymphatic system cancer	0.00396	0.00396	CcSEcCtD
Bepridil—Body temperature increased—Bleomycin—lymphatic system cancer	0.00394	0.00394	CcSEcCtD
Bepridil—Insomnia—Carmustine—lymphatic system cancer	0.00393	0.00393	CcSEcCtD
Bepridil—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00391	0.00391	CcSEcCtD
Bepridil—Paraesthesia—Carmustine—lymphatic system cancer	0.0039	0.0039	CcSEcCtD
Bepridil—Dyspnoea—Carmustine—lymphatic system cancer	0.00388	0.00388	CcSEcCtD
Bepridil—Somnolence—Carmustine—lymphatic system cancer	0.00386	0.00386	CcSEcCtD
Bepridil—Anorexia—Mitoxantrone—lymphatic system cancer	0.00385	0.00385	CcSEcCtD
Bepridil—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.00378	0.00378	CcSEcCtD
Bepridil—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00378	0.00378	CcSEcCtD
Bepridil—Decreased appetite—Carmustine—lymphatic system cancer	0.00378	0.00378	CcSEcCtD
Bepridil—Insomnia—Vincristine—lymphatic system cancer	0.00375	0.00375	CcSEcCtD
Bepridil—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00375	0.00375	CcSEcCtD
Bepridil—Paraesthesia—Vincristine—lymphatic system cancer	0.00373	0.00373	CcSEcCtD
Bepridil—Constipation—Carmustine—lymphatic system cancer	0.00372	0.00372	CcSEcCtD
Bepridil—Pain—Carmustine—lymphatic system cancer	0.00372	0.00372	CcSEcCtD
Bepridil—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00368	0.00368	CcSEcCtD
Bepridil—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00363	0.00363	CcSEcCtD
Bepridil—Decreased appetite—Vincristine—lymphatic system cancer	0.00361	0.00361	CcSEcCtD
Bepridil—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.0036	0.0036	CcSEcCtD
Bepridil—Somnolence—Mitoxantrone—lymphatic system cancer	0.00359	0.00359	CcSEcCtD
Bepridil—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00358	0.00358	CcSEcCtD
Bepridil—Asthenia—Bleomycin—lymphatic system cancer	0.00357	0.00357	CcSEcCtD
Bepridil—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00356	0.00356	CcSEcCtD
Bepridil—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00355	0.00355	CcSEcCtD
Bepridil—Pain—Vincristine—lymphatic system cancer	0.00355	0.00355	CcSEcCtD
Bepridil—Constipation—Vincristine—lymphatic system cancer	0.00355	0.00355	CcSEcCtD
Bepridil—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00351	0.00351	CcSEcCtD
Bepridil—Pain—Mitoxantrone—lymphatic system cancer	0.00346	0.00346	CcSEcCtD
Bepridil—Constipation—Mitoxantrone—lymphatic system cancer	0.00346	0.00346	CcSEcCtD
Bepridil—Body temperature increased—Carmustine—lymphatic system cancer	0.00344	0.00344	CcSEcCtD
Bepridil—Abdominal pain—Carmustine—lymphatic system cancer	0.00344	0.00344	CcSEcCtD
Bepridil—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.00339	0.00339	CcSEcCtD
Bepridil—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00339	0.00339	CcSEcCtD
Bepridil—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.0033	0.0033	CcSEcCtD
Bepridil—Abdominal pain—Vincristine—lymphatic system cancer	0.00328	0.00328	CcSEcCtD
Bepridil—Body temperature increased—Vincristine—lymphatic system cancer	0.00328	0.00328	CcSEcCtD
Bepridil—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.00326	0.00326	CcSEcCtD
Bepridil—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00319	0.00319	CcSEcCtD
Bepridil—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00319	0.00319	CcSEcCtD
Bepridil—Drowsiness—Methotrexate—lymphatic system cancer	0.00316	0.00316	CcSEcCtD
Bepridil—Depression—Methotrexate—lymphatic system cancer	0.00315	0.00315	CcSEcCtD
Bepridil—Rash—Bleomycin—lymphatic system cancer	0.00314	0.00314	CcSEcCtD
Bepridil—Dermatitis—Bleomycin—lymphatic system cancer	0.00314	0.00314	CcSEcCtD
Bepridil—Asthenia—Carmustine—lymphatic system cancer	0.00312	0.00312	CcSEcCtD
Bepridil—Sweating—Methotrexate—lymphatic system cancer	0.00303	0.00303	CcSEcCtD
Bepridil—Asthenia—Vincristine—lymphatic system cancer	0.00298	0.00298	CcSEcCtD
Bepridil—Diarrhoea—Carmustine—lymphatic system cancer	0.00297	0.00297	CcSEcCtD
Bepridil—Nausea—Bleomycin—lymphatic system cancer	0.00296	0.00296	CcSEcCtD
Bepridil—Asthenia—Mitoxantrone—lymphatic system cancer	0.0029	0.0029	CcSEcCtD
Bepridil—Dizziness—Carmustine—lymphatic system cancer	0.00287	0.00287	CcSEcCtD
Bepridil—Diarrhoea—Vincristine—lymphatic system cancer	0.00284	0.00284	CcSEcCtD
Bepridil—Pharyngitis—Methotrexate—lymphatic system cancer	0.00281	0.00281	CcSEcCtD
Bepridil—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00277	0.00277	CcSEcCtD
Bepridil—Dizziness—Vincristine—lymphatic system cancer	0.00274	0.00274	CcSEcCtD
Bepridil—Rash—Carmustine—lymphatic system cancer	0.00274	0.00274	CcSEcCtD
Bepridil—Dermatitis—Carmustine—lymphatic system cancer	0.00274	0.00274	CcSEcCtD
Bepridil—Headache—Carmustine—lymphatic system cancer	0.00272	0.00272	CcSEcCtD
Bepridil—Tinnitus—Methotrexate—lymphatic system cancer	0.00264	0.00264	CcSEcCtD
Bepridil—Cardiac disorder—Methotrexate—lymphatic system cancer	0.00263	0.00263	CcSEcCtD
Bepridil—Rash—Vincristine—lymphatic system cancer	0.00262	0.00262	CcSEcCtD
Bepridil—Dermatitis—Vincristine—lymphatic system cancer	0.00261	0.00261	CcSEcCtD
Bepridil—Headache—Vincristine—lymphatic system cancer	0.0026	0.0026	CcSEcCtD
Bepridil—Nausea—Carmustine—lymphatic system cancer	0.00258	0.00258	CcSEcCtD
Bepridil—Rash—Mitoxantrone—lymphatic system cancer	0.00255	0.00255	CcSEcCtD
Bepridil—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00255	0.00255	CcSEcCtD
Bepridil—Headache—Mitoxantrone—lymphatic system cancer	0.00253	0.00253	CcSEcCtD
Bepridil—Nausea—Vincristine—lymphatic system cancer	0.00246	0.00246	CcSEcCtD
Bepridil—Nausea—Mitoxantrone—lymphatic system cancer	0.0024	0.0024	CcSEcCtD
Bepridil—Vision blurred—Methotrexate—lymphatic system cancer	0.00233	0.00233	CcSEcCtD
Bepridil—Vertigo—Methotrexate—lymphatic system cancer	0.00222	0.00222	CcSEcCtD
Bepridil—Cough—Methotrexate—lymphatic system cancer	0.00215	0.00215	CcSEcCtD
Bepridil—Myalgia—Methotrexate—lymphatic system cancer	0.0021	0.0021	CcSEcCtD
Bepridil—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Bepridil—Anorexia—Methotrexate—lymphatic system cancer	0.00192	0.00192	CcSEcCtD
Bepridil—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Bepridil—Insomnia—Methotrexate—lymphatic system cancer	0.00182	0.00182	CcSEcCtD
Bepridil—Paraesthesia—Methotrexate—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Bepridil—Dyspnoea—Methotrexate—lymphatic system cancer	0.0018	0.0018	CcSEcCtD
Bepridil—Somnolence—Methotrexate—lymphatic system cancer	0.00179	0.00179	CcSEcCtD
Bepridil—Dyspepsia—Methotrexate—lymphatic system cancer	0.00177	0.00177	CcSEcCtD
Bepridil—Decreased appetite—Methotrexate—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Bepridil—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.00174	0.00174	CcSEcCtD
Bepridil—Pain—Methotrexate—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Bepridil—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.00165	0.00165	CcSEcCtD
Bepridil—Abdominal pain—Methotrexate—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Bepridil—Body temperature increased—Methotrexate—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Bepridil—Asthenia—Methotrexate—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Bepridil—Diarrhoea—Methotrexate—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Bepridil—Dizziness—Methotrexate—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Bepridil—Rash—Methotrexate—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Bepridil—Dermatitis—Methotrexate—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Bepridil—Headache—Methotrexate—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Bepridil—Nausea—Methotrexate—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
